Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-02-01FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Neolpharma, Inc.)
FDA approved Neolpharma, Inc.'s methylphenidate hydrochloride generic under an original ANDA. The product is indicated for attention-deficit…
-
CLINICAL_TRIALS research · 2019-01-25Clinical Trial Update: Tics in Childern With Acute Deficit Hyper Activity Syndrom
This entry provides a clinical trial update on tic disorders in children with attention deficit hyperactivity disorder, sponsored by Assiut …
-
FDA approval · 2019-01-22FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (ANI Pharmaceuticals, Inc.)
FDA approves ANI Pharmaceuticals' generic combination of amphetamine salts (dextroamphetamine saccharate, amphetamine aspartate monohydrate,…
-
CLINICAL_TRIALS research · 2019-01-22Clinical Trial Update: Investigating the Relationship Between Parents and Their Children With ADHD and Conduct Disorder
An observational study exploring how parental relationships relate to children with ADHD and conduct disorder; the current trial status is n…
-
FDA approval · 2019-01-15FDA Approved: DEXEDRINE SPANSULE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Dexedrine Spansule (dextroamphetamine sulfate) from Amneal Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2019-01-10FDA Approved: FOCALIN — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for FOCALIN from Sandoz Inc, updating the product labeling based on the submitted supplement.
-
FDA approval · 2019-01-10FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) submitted by Sandoz Inc.
-
FDA approval · 2019-01-10FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for methylphenidate from Sandoz Inc, supporting continued marketing of the product.
-
FDA approval · 2018-12-13FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Actavis Pharma, Inc.)
FDA approved Actavis Pharma, Inc.'s methylphenidate hydrochloride generic under an original application (ANDA 208861).
-
FDA approval · 2018-12-07FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Elite Laboratories, Inc.)
FDA approved Elite Laboratories, Inc.'s original ANDA for a combination amphetamine product consisting of dextroamphetamine saccharate, amph…
-
FDA approval · 2018-11-21FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Granules Pharmaceuticals Inc.)
FDA approved Granules Pharmaceuticals Inc.'s methylphenidate hydrochloride generic under an original ANDA.
-
CLINICAL_TRIALS withdrawal · 2018-11-01Clinical Trial Update: A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD [Phase 4]
A Phase 4 trial evaluating methylphenidate HCl ERCT in 4-5 year old children with ADHD was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-11-01Clinical Trial Update: A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. [Phase 4]
A Phase 4 clinical trial evaluating Quillichew ERCT in 4-5 year old children with ADHD was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-11-01Clinical Trial Update: Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. [Phase 4]
A Phase 4 safety, tolerability, and pharmacokinetics study of extended-release methylphenidate in 4- to 5-year-olds with ADHD has been withd…
-
CLINICAL_TRIALS trial_result · 2018-10-25Clinical Trial Update: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder [Phase 2]
Phase 2 trial update for SPD489 in preschool children with ADHD reports on safety, tolerability, pharmacokinetics, and efficacy.
-
CLINICAL_TRIALS trial_result · 2018-10-23Clinical Trial Update: Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits [Phase 2]
Phase 2 trial evaluating omega-3 fatty acid supplementation added to ADHD pharmacotherapy in adults with ADHD and DESR; study completed with…
-
FDA approval · 2018-10-12FDA Approved: CLONIDINE HYDROCHLORIDE — Original Application (Somerset Therapeutics, LLC)
FDA approved Somerset Therapeutics' clonidine hydrochloride as a generic drug under an Original Application. The approval supports the gener…
-
FDA approval · 2018-10-09FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE — Original Application (Lannett Company, Inc.)
FDA approved the original application for a generic dexmethylphenidate hydrochloride extended-release product from Lannett Company, Inc., es…
-
CLINICAL_TRIALS trial_result · 2018-10-03Clinical Trial Update: A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting [Phase 3]
A pivotal Phase 3 trial evaluating HLD200 for attention deficit hyperactivity disorder in children has completed; results are posted.
-
CLINICAL_TRIALS trial_result · 2018-10-03Clinical Trial Update: A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting [Phase 3]
A pivotal Phase 3 efficacy trial evaluating HLD200 in children with ADHD has completed; results were posted in 2018.
-
FDA approval · 2018-10-03FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Eywa Pharma Inc)
FDA approved Eywa Pharma Inc's methylphenidate hydrochloride under an original ANDA, adding a generic option for ADHD treatment.
-
FDA approval · 2018-09-26FDA Approved: AMPHETAMINE SULFATE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic amphetamine sulfate under an Original Application, enabling a generic version of this s…
-
FDA approval · 2018-09-19FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Nivagen Pharmaceuticals, Inc.)
FDA approved the original ANDA for a generic dexmethylphenidate hydrochloride product manufactured by Nivagen Pharmaceuticals, Inc., for the…
-
CLINICAL_TRIALS trial_result · 2018-09-12Clinical Trial Update: Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too) [Phase 4]
Phase 4 clinical trial update on treatments for fathers with ADHD and their at-risk children.
-
CLINICAL_TRIALS trial_result · 2018-09-07Clinical Trial Update: Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD [Phase 4]
Phase 4 clinical trial update evaluating network connectivity and inhibitory control under atomoxetine challenge in patients with ADHD; stud…